Long-acting beta₂-adrenergic agonist in pediatric and adolescent asthma patients, 2003–2011

References

• Center for Disease Control and Prevention. National Center for Health Statistics. Health Data Interactive. Summary Health Statistics for U.S. Children: National Health Interview Survey, 2011, Table 1. Available from: http://www.cdc.gov/nchs/fastats/asthma.htm [last accessed 17 July 2013]
   Google Scholar
• National Asthma Education and Prevention Program. 2007. Expert panel report 3: guidelines for the diagnosis and management of asthma. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm [last accessed 8 July 2013]
   Google Scholar
• Sears MR. Safe use of long-acting β-agonists: what have we learnt? Expert Opin Drug Saf 2011;10:767–778
   PubMed Web of Science ®Google Scholar
• Perera BJ. Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths. Ceylon Med J 2003;48:99
   Google Scholar
• Wooltorton E. Salmeterol (Serevent) asthma trial halted early. CMAJ 2003;168:738
   Google Scholar
• Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists – the influence of values. N Engl J Med 2009;360:1592–5
   Google Scholar
• Martinez FD. Safety of long-acting beta-agonists – an urgent need to clear the air. N Engl J Med 2005;353:2637–2639
   PubMed Web of Science ®Google Scholar
• Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009;33:21–32
   Google Scholar
• Long-Acting Beta Agonist (LABA) Information. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm199565.htm [last accessed 8 July 2013]
   Google Scholar
• FDA Drug Safety Communication: new safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs) 2/18/2010. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm [last accessed 8 July 2013]
   Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. New Engl J Med 2010;362:1169–71. doi: 10.1056/NEJMp1002074. Epub 2010 Feb 24
   Google Scholar
• McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-adrenergic receptor agonists. Pediatrics 2011;128:e1147–e1154
   Google Scholar
• Kaplan S, Zhou EH, Iyasu S. Characterization of long-acting beta(2)-adrenergic agonists utilization in asthma patients. J Asthma 2012;49:1079–1085
   PubMed Web of Science ®Google Scholar
• Agresti A. An introduction to categorical data analysis. 2nd ed. New York: John Wiley & Sons; 2007
   Google Scholar
• Dal Pan, GJ. Communicating the risks of medicines: time to move forward. Med Care 2012;50:463–465
   Google Scholar
• National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics – 2002. J Allergy Clin Immunol 2002;110:S141–S219
   PubMed Web of Science ®Google Scholar
• Kit BK, Simon AE, Ogden CL, Akinbami LJ. Trends in preventive asthma medication use among children and adolescents, 1988–2008. Pediatrics 2012;129:62–69
   PubMed Web of Science ®Google Scholar
• Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. Clin Ther 2009;31:1056–1063
   PubMed Web of Science ®Google Scholar
• Stockl KM, Le L, Harada AS, Zhang S. Use of controller medications in patients initiated on a longacting beta2-adrenergic agonist before and after safety alerts. Am J Health Syst Pharm 2008;65:1533–1538
   Google Scholar
• Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Curr Med Res Opin 2009;25:2251–2258
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Davis KJ. Prescription patterns in asthma patients initiating salmeterol in UK general practice: a retrospective cohort study using the General Practice Research Database (GPRD). Drug Saf 2011;34:511–520
   Google Scholar
• The US Department of Justice, Office of Public Affairs. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. IMMEDIATE RELEASE: July 2, 2012. Available from: http://www.justice.gov/opa/pr/2012/July/12-civ-842.html [last accessed 2 May 2014]
   Google Scholar
• Hurley MP, Stafford RS, Lane AT. Characterizing the relationship between free drug samples and prescription patterns for acne vulgaris and rosacea. JAMA Dermatol 2014;150:487–493
   PubMed Web of Science ®Google Scholar
• Adair RF, Holmgren LR. Do drug samples influence resident prescribing behavior? A randomized trial. Am J Med 2005;118:881–884
   PubMed Web of Science ®Google Scholar
• Rouleau R, Beauchesne MF, Laurier C. Impact of a continuing education program on community pharmacists' interventions and asthma medication use: a pilot study. Ann Pharmacother 2007;41:574–580
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001–2009. MMWR Morb Mortal Wkly Rep 2011;60:547–552
   PubMedGoogle Scholar
• Stevens D, Sharma K, Kesten S. Insurance status and patient behavior with asthma medications. J Asthma 2003;40:789–793
   PubMed Web of Science ®Google Scholar